Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
Diabetic nephropathy (DN) has emerged as the major causative pathology in patients entering end-stage renal disease (ESRD) worldwide and it is responsible for 30-40% of all ESRD cases. Treatments for DN are centered on control of hyperglycemia and blood p..... Read More